Equivalent normalized total dose estimates in cyberknife radiotherapy dose delivery in prostate cancer hypofractionation regimens.

Journal of Medical Physics
H SudaharJ Velmurugan

Abstract

As the α/β value of prostate is very small and lower than the surrounding critical organs, hypofractionated radiotherapy became a vital mode of treatment of prostate cancer. Cyberknife (Accuray Inc., Sunnyvale, CA, USA) treatment for localized prostate cancer is performed in hypofractionated dose regimen alone. Effective dose escalation in the hypofractionated regimen can be estimated if the corresponding conventional 2 Gy per fraction equivalent normalized total dose (NTD) distribution is known. The present study aims to analyze the hypofractionated dose distribution of localized prostate cancer in terms of equivalent NTD. Randomly selected 12 localized prostate cases treated in cyberknife with a dose regimen of 36.25 Gy in 5 fractions were considered. The 2 Gy per fraction equivalent NTDs were calculated using the formula derived from the linear quadratic (LQ) model. Dose distributions were analyzed with the corresponding NTDs. The conformity index for the prescribed target dose of 36.25 Gy equivalent to the NTD dose of 90.63 Gy (α/β = 1.5) or 74.31 Gy (α/β = 3) was ranging between 1.15 and 1.73 with a mean value of 1.32 ± 0.15. The D5% of the target was 111.41 ± 8.66 Gy for α/β = 1.5 and 90.15 ± 6.57 Gy for α/β = 3. Similarl...Continue Reading

References

Jul 1, 1988·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·A J van der KogelM R Raju
Dec 1, 1986·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·B MaciejewskiH R Withers
Apr 7, 1999·International Journal of Radiation Oncology, Biology, Physics·D J Brenner, E J Hall
Mar 11, 2003·Technology in Cancer Research & Treatment·Christopher R KingJenny Hai
Jun 28, 2003·International Journal of Radiation Oncology, Biology, Physics·Jack F FowlerDavid J Brenner
Nov 24, 2004·Physics in Medicine and Biology·David J CarlsonM Guerrero
Jun 23, 2006·Physics in Medicine and Biology·Jack F Fowler
Aug 23, 2008·International Journal of Radiation Oncology, Biology, Physics·Abrahim Al-MamganiJoos V Lebesque
Sep 17, 2009·Technology in Cancer Research & Treatment·Jay L FriedlandDavid M Spellberg
Sep 22, 2009·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Dirk WolffFrank Lohr
Dec 3, 2009·American Journal of Clinical Oncology·Alvaro A MartinezGary S Gustafson
Sep 8, 2010·Technology in Cancer Research & Treatment·Alan J Katz
Jan 12, 2011·Radiation Oncology·Debra E Freeman, Christopher R King

❮ Previous
Next ❯

Software Mentioned

Multiplan

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.

© 2021 Meta ULC. All rights reserved